Aiforia Technologies Oyj

Research Aiforia Technologies Oyj (AIFORIA) on Bullrun: market cap EUR 40.23M, P/E 2.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 40.23M; P/E is 2.6.

Peer valuation comparison

Latest P/E is 2.62x versus a Healthcare sector median of 24.46x (89.3% below).

Latest P/E is 2.62x versus a Finland median of 18.47x (85.8% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 3.54M-EUR 12.67M-EUR 14.24M73.4%0.41EUR 9.53MEUR 7.18MEUR 17.05M
FY2024EUR 2.85M-EUR 11.95M-EUR 13.40M78.9%-0.43EUR 11.50MEUR 6.56MEUR 16.57M
FY2023EUR 2.40M-EUR 12.93M-EUR 14.15M80.6%-0.5EUR 13.97MEUR 5.85MEUR 17.91M
FY2022EUR 1.61M-EUR 12.16M-EUR 15.24M64.5%-0.47EUR 24.70MEUR 3.72MEUR 29.30M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24EUR 40.23M2.6n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About Aiforia Technologies Oyj

Aiforia Technologies Oyj, together with its subsidiary, Aiforia Inc., provides AI-based image analysis software used in clinical, preclinical, and academic laboratories to pathologists and researchers in Finland, rest of Europe, North America, and internationally. It offers tools for AI-supported diagnostics and visualization of patient samples, as well as automated screening and reporting tools for the treatment of various cancers, such as breast, lung, and prostate cancer;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Aiforia Technologies Oyj's market cap?

Aiforia Technologies Oyj's market capitalization is EUR 40.23M.

What is Aiforia Technologies Oyj's P/E ratio?

Aiforia Technologies Oyj's price-to-earnings (P/E) ratio is 2.6.

What does Aiforia Technologies Oyj do?

Aiforia Technologies Oyj, together with its subsidiary, Aiforia Inc., provides AI-based image analysis software used in clinical, preclinical, and academic laboratories to pathologists and researchers in Finland, rest of Europe, North America, and internationally.